About Caidya
Caidya is a Healthcare company based in Morrisville (United States) founded in 2003. CRO focused on clinical development for phases II III clinical trials and regulatory affair services. Caidya has raised $373 million across 5 funding rounds from investors including Fidelity Investments, Kaiser Permanente and Zai Lab. The company has 351 employees. Its focus areas include Biopharma Outsourcing and Diversified. Its legal entity is CLINIPACE INC. Its competitors include ANI Pharmaceuticals, Red Nucleus and Aptar.
Company details
Caidya was established in 2003 and is headquartered in Morrisville, United States. As a contract research organization, focus is placed on clinical development for phases II and III trials within the pharmaceutical and biotechnology sectors. Regulatory affairs services are also delivered to assist with compliance and approval processes. Operations support clients through structured trial management and advisory expertise in a regulated environment.
- Headquarters Morrisville, United States
- Employees 351
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website caidya.com
- Social LinkedIn X Instagram
- Legal Name Clinipace Inc
- Total Equity Funding$373M (USD)
in 5 rounds
- Latest Funding Round$165M (USD), Private Equity Round
Jan 2025
- InvestorsFidelity Investments
& 12 more
- Employee Count351
Funding Insights of Caidya
Caidya has successfully raised a total of $373M across 5 strategic funding rounds. The most recent funding activity was a Private Equity Round of $165 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $373M
- Total Rounds 5
- Last Round Private Equity Round — $165M
- First Round $8M
(Nov 2016)
- Investors Count 13
All 5 funding rounds of Caidya with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2025 | $165M | Private Equity Round | – | – | |
| Jul 2021 | $50M | Series C | – | SpringHill Management | |
| Dec 2020 | $100M | Series C | – | Fidelity Investments | |
| Oct 2019 | $50M | Series B | – | Vivo Capital | |
| Nov 2016 | $8M | Series A | – | Qiming Venture Partners, Lilly Asia Ventures |
13 investors in total: 13 institutional.
Investors in Caidya
Caidya has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, Kaiser Permanente and Zai Lab.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare investment firm focused on building transformational companies. | rubiconfounders.com | Nashville, United States | ||
UK life science startups are invested in by SpringHill Management. | springhilluk.com | Guildford, United Kingdom | ||
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
Venture capital and private equity investments are made across technologies. | hsgcap.com | Hong Kong, China | ||
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
Venture Capital firm focused on multiple sectors | legendcapital.com.cn | Haidian, China | ||
Venture capital investments are directed toward multiple sectors. | 2006 | qimingvc.com | Shanghai, China | |
Investments in biomedical companies are directed by Lilly Asia Ventures. | lavasset.com | Huangpu, China | ||
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms | 1946 | fidelity.com | Boston, United States | |
Integrated healthcare services and coverage are provided nationwide. | 1945 | kaiserpermanente.org | United States |
Investor details for Caidya
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Caidya
3 dated milestones of Caidya across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Caidya is founded.
- Funding First funding round of $8.0M.
- Funding Latest funding round, Private Equity Round, of $165.0M.
Competitors of Caidya
Caidya has 3 listed competitors in our database. They include ANI Pharmaceuticals, Red Nucleus and Aptar.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| anipharmaceuticals.com | 1996 | Baudette, United States | 600 | Branded and generic prescription drugs are developed, manufactured, and marketed. | ||
| rednucleus.com | 2014 | Yardley, United States | 176 | Advisory, scientific, and medical communications provided for pharmaceutical industry. | ||
| aptar.com | 1992 | Crystal Lake, United States | 232 | Regulatory support, brand differentiation, and prototyping services are provided. |
Detailed competitors of Caidya
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Caidya
The website of Caidya (caidya.com) receives about 8.4K visits a month and ranks #3,322,113 among all websites worldwide, #4,368 in Biotechnology and Pharmaceuticals.
- Monthly visits8.4K
▲ 44.5% vs previous month
- Unique visitors2.5K
per month
- Global rank#3,322,113
among all websites
- Category rank#4,368
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit1.8
- Average visit33 sec
- DevicesDesktop 40% · Mobile 60%
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Caidya (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Caidya
Complete news archive for Caidya
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Caidya
Caidya was founded in 2003 and raised its 1st funding round 13 years after it was founded.
Caidya is headquartered in Morrisville, United States.
Caidya is a funded company, having raised a total of $373M across 5 funding rounds to date. The company's 1st funding round was a Series A of $8M, raised on Nov 2016.
Caidya has 351 employees.
Caidya was established in 2003 and is headquartered in Morrisville, United States. As a contract research organization, focus is placed on clinical development for phases II and III trials within the pharmaceutical and biotechnology sectors. Regulatory affairs services are also delivered to assist with compliance and approval processes. Operations support clients through structured trial management and advisory expertise in a regulated environment.
Caidya's top competitors include ANI Pharmaceuticals, Aptar and Red Nucleus.
Caidya has 13 investors. Key investors include Fidelity Investments, Kaiser Permanente, Zai Lab, Qiming Venture Partners, and Rubicon Founders.
Caidya operates through Clinipace Inc.